These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 37810157)

  • 1. Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome.
    Guo X; Yu S; Ren X; Li L
    Heliyon; 2023 Sep; 9(9):e19222. PubMed ID: 37810157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune dysregulation and potential targeted therapy in myelodysplastic syndrome.
    Zhang X; Yang X; Ma L; Zhang Y; Wei J
    Ther Adv Hematol; 2023; 14():20406207231183330. PubMed ID: 37547364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging strategies for management of myelodysplastic syndromes.
    Saygin C; Carraway HE
    Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
    Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
    Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow free immune checkpoints as a potential biomarker for differential diagnosis of acquired bone marrow failures.
    Zang M; Li N; Chen Q; Ran N; Fu R; Shao Z; Wang T
    J Clin Lab Anal; 2022 Oct; 36(10):e24677. PubMed ID: 36086857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic changes of monocytes in myelodysplastic syndrome and clinical significance.
    Li L; Yu S; Hu X; Liu Z; Tian X; Ren X; Guo X; Fu R
    Clin Exp Med; 2023 Jul; 23(3):787-801. PubMed ID: 35916958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
    Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIM3/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8
    Yu S; Ren X; Meng F; Guo X; Tao J; Zhang W; Liu Z; Fu R; Li L
    Immunology; 2023 Feb; 168(2):273-289. PubMed ID: 35470423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis.
    Moiseev I; Tcvetkov N; Epifanovskaya O; Babenko E; Parfenenkova A; Bakin E; Yurovskaya K; Morozova E
    PLoS One; 2022; 17(10):e0275399. PubMed ID: 36282797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Patients Aged Over 60 Years.
    Chaudhuri D; Khan KI; Al Shouli R; Allakky A; Ferguson AA; Khan AI; Abuzainah B; Gutlapalli SD; Hamid P
    Cureus; 2023 Jun; 15(6):e40124. PubMed ID: 37425516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.
    Choi EJ; Cho YU; Hur EH; Park HS; Choi Y; Lee JH; Lee KH; Kim M; Hwang SH; Jang S; Park CJ; Seo EJ; Lee JH
    Br J Haematol; 2022 Aug; 198(4):703-712. PubMed ID: 35612271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global Proteomics Analysis of Bone Marrow: Establishing Talin-1 and Centrosomal Protein of 55 kDa as Potential Molecular Signatures for Myelodysplastic Syndromes.
    Moura AA; Bezerra MJB; Martins AMA; Borges DP; Oliveira RTG; Oliveira RM; Farias KM; Viana AG; Carvalho GGC; Paier CRK; Sousa MV; Fontes W; Ricart CAO; Moraes MEA; Magalhães SMM; Furtado CLM; Moraes-Filho MO; Pessoa C; Pinheiro RF
    Front Oncol; 2022; 12():833068. PubMed ID: 35814389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
    Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
    Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.
    Zheng L; Zhang L; Guo Y; Xu X; Liu Z; Yan Z; Fu R
    Front Immunol; 2022; 13():1078421. PubMed ID: 36569863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYELODYSPLASTIC SYNDROME: DIAGNOSIS, TREATMENT AND PROGNOSIS (LITERATURE REVIEW).
    Baidurin S; Akhmetzhanova S; Ilmalieva A; Sagyndykova G; Orazbekova A
    Georgian Med News; 2023 Jan; (334):103-107. PubMed ID: 36864802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of immune checkpoint based approaches in AML and MDS.
    Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
    Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoplastic form of myelodysplastic neoplasm.
    Votavová H; Lenertová Z; Votava T; Beličková M
    Klin Onkol; 2023; 36(3):206-214. PubMed ID: 37353349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome.
    Tcvetkov N; Gusak A; Morozova E; Moiseev I; Baykov V; Barabanshikova M; Lepik K; Bakin E; Vlasova J; Osipova A; Zubarovskaya L; Afanasyev B
    Leuk Res Rep; 2020; 14():100215. PubMed ID: 32695574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.